Exhibit 99.1

This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries, including Biomica Ltd. (“Biomica”) (collectively, “Evogene” or “we”), that are considered “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the “PSLRA”) and other securities laws. Such forward-looking statements may be identified by the use of such words as “believe,” “expect,” “anticipate,” “should,” “planned,” “estimated,” “intend” and “potential” or words of similar meaning. For these statements, Biomica claims the protection of the safe harbor for forward-looking statements contained in the PSLRA and other securities laws. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Biomica and Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Biomica's and Evogene's control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information it files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading “Risk Factors.” Forward-looking statement All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirely by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Biomica and Evogene disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions. The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene. The trademarks included herein are the property of the ownersthereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

An emerging biopharmaceutical company with cutting edge computational capabilities to develop the most optimized microbiome-based therapeutics. Rooted in excellence We are Biomica Drug candidates identified and designed with PRISM – a proprietary computational platform combining AI capabilities with big data. Optimized discovery, design & development, resulting in best-in-class pharmaceuticals.Precise & efficient – from concept to clinical trials in only 3 years. Subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), a pioneer in the field of applied computational predictive biology, creating next-generation life sciences products. Breakthrough platform Spearheading the future

Our Mission Current programs: Gastrointestinal (GI) related disorders Antimicrobial resistance (AMR) Showing promise in immune-mediated & infectious diseases Immuno-oncology To discover & develop novel therapies formicrobiome-related human disorders. We utilize computational predictive biology to provide new therapeutic modalities for high-value, unmet medical needs.

10 14 microbesin thehuman body Trillions of microorganisms live in & on our bodiesPlay an essential role in various daily bodily functionsMicrobiome diversity is associated with health & wellbeing Harnessing the human microbiome

Right field, right time Sources: BCC Research (2017) – Human Microbiome-based Drugs and Diagnostics Market SVB – Emerging Healthcare: Microbiome Investment Trends Aug 2017)https://www.microbiometimes.com/the-microbiome-biotech-landscape-an-analysis-of-the-pharmaceutical-pipeline/ Industry Big pharma Most candidates are still in the discovery & preclinical stages; Increasing number advancing to clinical stage (Ph. II/III) Areas of focus Multi $Bn market opportunityMore than $4Bn invested in microbiome companies since 2014 Record high investmentsIn microbiome companies Prominent VCs Active companies Dermatology (8%)CNS (7%)Other (6%)GI-related disorders (44%)Cancer & Immune-mediated Diseases (35%) Key Players 6% 7% 8% 35% 44% 70% CAGR 2024 2018

The microbiomeis flourishing Right field, right time A clinical promisecomes true Positive phase 3 clinical data shows strong validation of microbiome therapeutics. Aug 10, 2020 June 19, 2020 11 September 2020 17 June, 2021 26 January, 2021 2 July, 2021 30 November, 2020

Fecal Microbiota Transplantation (FMT) Single-strain method Multi-strain rationally-designed Live biotherapeutic products (LBPs) ** Better safety due to fewer & carefully selected entities * Higher efficacy due to multiple carefully selected MoAs Limitations of common approaches Number of microbial entities QC Scalability Druggability Patentability COGS Targeted multiple functions composition Potency* Safety** Fully addressed Partial addressed Not addressed

Finding the optimal combinationof microbes is complex To develop best-in-class drugs, one must find, select, and combineonly the most suitable microbes from the thousands of strains in our bodies. Each method has its own set of challenges Biological method:Healing the sick by comparing them to the healthy Computational method:Using AI to findthe key microbes Slow & exhaustingLimited by small data Like finding needle in the hay Lack of proper tools & datasetsPoor ability to gain valuable insights

Computational, targeted& function-based drug design Modulatinga patient’s microbiome Computational predictive biology platform Function-baseddrug design process The approach: 2 1 3

Modulatinga patient’s microbiome 1 Immuno-oncology or GI disorders Infections caused by multi-drug resistant bacteria Reduced diversityLoss of beneficial microbesOpportunist’s expansion EliminationSelective targeting via small molecules, peptide(s) SupplementationAdding beneficial bacteria Initial state:Dysbiosis Desired state:Homeostasis(balance)

Computational predictive biology platform Proprietary computational algorithms utilized to mine data Big data $$$tens of millions of dollars invested Validationthrough collaborations with industrial leaders & internal results Proven, robust data integration, analysis & prediction Databases generated via data integration capabilities Biology AI 2 20 yearsof experience

Analysis, integration&prioritization Computational & researcher-guided selection of candidate microbes Computational predictive biology platform 2 Patients’ microbiome:Identifies the strains present & the functions they perform Strain identifierFunction finderStrain-functionallocator Patients’ genetic & clinical data:Examining the patient’s clinical data & genomic data Clinical dataHuman genomicsConsolidator Drug Holistically determining the best strains for the patient

Function based drug design process 3 An emphasis on microbial function The optimal combination PRISM allows high resolution analysis to rationally design therapeutics based on microbial functions*.This differentiates Biomica from current practices. Up to 4 bacterial strains are carefully-selected, based on their functions, which may work across several complementary mechanisms. * Functions:Genetic elements (e.g. genes, operons, pathway, plasmids) and/or their biosynthetic products (e.g. metabolites, proteins, enzymes) Current practices Biomica Name: DX13756Functional profile:Fully mappedContribution to functions of interest 9/10Modes of actions affected: 5/5Overall score: 9.75 Name: DX13756Functional profile:Fully mappedContribution to functions of interest 9/10Modes of actions affected: 5/5Overall score: Minimum no. of microbial strainsMaximumrelevant & complementary functionsOptimal therapeutic impact

Fully addressed Partial addressed Not addressed Fully addressed Partial addressed Not addressed Fecal Microbiota Transplantation (FMT) Single-strain method Multi-strain rationally-designed LBPs Biomica’s rationally-designed LBPs ** Better safety due to fewer & carefully selected entities * Higher efficacy due to multiple carefully selected MoAs Biomica’s optimal therapeutic outcome Number of microbial entities QC Scalability Druggability Patentability COGS Targeted multiple functions composition Potency* Safety**

Immuno-oncology BMC128 Combination Therapywith ICI* for Solid Tumors GI-related disorders BMC333 IBD BMC426 IBS Antimicrobial resistance (AMR( BMC202 C. difficile Infection TBD** MRSA Infection * Immune checkpoint inhibitors **Biomica in collaboration with Nobel Prize Laureate Prof. Ada Yonath at Weizmann Institute of Science to develop a selective treatment for MRSA infection. The pipeline Live biotherapeutics Small-molecule Program Indication / Target Discovery Preclinical Phase 1 /POC Phase 2 Approach

Cancer immunotherapy 1 Response to immunotherapy through specific bacterial functions * Based on Biomica’s computational analysis Responders Non-responders SCFA productionInflammation Mucin turnover Innate immunity APC activityCD8+/CD4+ activityMethanogenesis Induction Suppression

POC in humans 1 Modulating gut microbiome improves cancer treatment www.sciencemag.org/news/2019/04/fecal-transplants-could-help-patients-cancer-immunotherapy-drugs Cancer immunotherapy …Now, another potential therapy is being tested in clinical studies: fecal transplants. Early results from two groups described at the annual meeting of the American Association for Cancer Research (AACR) here this week suggest some patients who initially did not benefit from immunotherapy drugs saw their tumors stop growing or even shrink after receiving a stool sample from patients for whom the drugs worked...…One unresolved question is exactly which microbes help ramp up the desired immune activity… “ “

www.science.org/doi/10.1126/science.abf3363 POC in humans 1 Modulating gut microbiome improves cancer treatment www.science.org/doi/10.1126/science.abb5920 Cancer immunotherapy Reports Clinical Trials

1 Cancer immunotherapy Combination therapy Initial focus on solid tumors: Lung cancer (NSCLC), renal cell carcinoma (RCC), and melanoma.Biomica aims to improve clinical response to ICI through immunomodulating combination therapy. Next gen. optimized consortiaA new combination providing the selected microbial functions& presenting higher likelihood for survival in GI. Consortium Micro-organism Microbial component / function Host response Interactions with other micro-organisms Cell envelope component SCFA production Lactate production Flagella Mucin degradation Dendritic cell activation and TH1 response CD4/8 activation NF-k8 activation TLR activation Gut health Consortium members General gut residents BMC127 BMCS111 BMCS114 BMCS115 BMCS117 Consortium Micro-organism Microbial component / function Host response Interactions with other micro-organisms Cell envelope component SCFA production Lactate production Flagella Mucin degradation Dendritic cell activation and TH1 response CD4/8 activation NF-k8 activation TLR activation TNFa Gut health Consortium members General gut residents BMC121 BMCS111 BMCS114 BMCS115 BMCS117 BMC128

1 Cancer immunotherapy Control The study indicates that pre-treatment with BMC128 conditions the immune system & primes it for an efficient anti-tumor response. BMC128 administered prior to and in combination with anti-PD1 significantly improved anti-tumor activity * BMC 128 - Comprised of 4 live bacterial strains derived from BMC121 and BMC127 8 September, 2020 Anti-PD1 BMC-128+ Anti-PD1 Pre-tx BMC-128 + Anti-PD1 100% 0% 50% Sacrificed during the studySurvived the study Pre-tx BMC-128 + Anti-PD1 Anti-PD1 100% 0% 50% PDSD CRPR ORR (CR+PR): 23.5% vs 34.8% 48% increase in responders Recist Survival Rate

1 Cancer immunotherapy These results demonstrate the potential applicability of BMC128 and its relevance to treating multiple types of solid tumors. BMC128 demonstrating efficacy against melanoma 13 April, 2021 BMC-128 + Anti-PD1 Control (untreated) 100% 0% 50% PDSD CRPR Recist Anti-PD1 BMC128 significantly enhanced anti-tumor activity, resulting in an increased response of melanoma tumors to anti-PD1 3 0 2 1 Tumor volume Day (post tumor inoculation) Control (untreated)Anti-PD1BMC128 + Anti-PD1 BMC128 demonstrates increased Objective Response Rate (ORR)No response in the Anti-PD1 group *** *** *

1 Cancer immunotherapy Advancing into the clinical phase BMC128 consists of 4 live bacterial strains.Results demonstrated a significant reduction of tumor volume, and increased animal survival compared to anti-PD1 therapy alone.MoA is immune mediated – Increased tumor inflammation & infiltration of T lymphocytes and NK cells.Potential applicability in the treatment various types of solid tumors. 13 October, 2020 Biomica completed large-scale GMP-production of BMC128 to support its first-in-human proof of concept clinical study, expected in early 2022

GI-related disorders 2 IBS & IBD Irritable bowel syndrome (IBS)* A common intestinal functional disorder, group of symptoms: Abdominal pain, constipation or diarrhea, bloating, gas & diarrhea. Inflammatory bowel disease (IBD) A group of inflammatory conditions of the colon and small intestine (Crohn's disease, ulcerative colitis & pouchitis). Both clearly related to the microbiome Biomica pushes the barriers posed by existing therapiesby addressing the underlying cause of the disorder, rather than the symptoms. PatientsEst. 43M IBS (40M)IBS-D (16M)IBS-C (14M)IBS-M (9M) IBD (3M)Crohn's disease (2M)Ulcerative colitis (1M)Pouchitis (150K) IBS ($1.5Bn) IBD ($19.2Bn) 20.7Bn USD https://www.grandviewresearch.com/industry-analysis/irritable-bowel-syndrome-ibs-treatment-market https://www.grandviewresearch.com/industry-analysis/inflammatory-bowel-disease-ibd-treatment-market *In collaboration with The University of North Carolina (UNC) at Chapel Hill

2 GI-related disorders Established role for microbiome in IBD etiology Drug comprised of 4 bacterial strains, detected through Biomica’s proprietary computational functional genomic analysis platform. A state of inflammation is associated with reduced richness of microbial taxa and functions Strains selected for their anti-inflammatory functions, complement each other and target both immunocytes and intestinal mucosal cells. Each strain supports growth and metabolism of other strains, along with favorable gut resident bacteria. BMC333 Aimed to reduce inflammation for treating IBD pubmed.ncbi.nlm.nih.gov/27769810/pubmed.ncbi.nlm.nih.gov/25595930/ Optimized drug candidate derived from Biomica’s drug candidates BMC321 and BMC322

2 GI-related disorders reduce inflammation in a DSS-treated mouse model* BMC321 & BMC322 indicate to Severe inflammation (% of total number of mice): Control - 43% VS. BMC322- 10% DSS only 100% 0% 50% SevereMild-moderate Inflammation statusDay 7 of DSS treatment DSS + BMC322 3000 0 2000 1000 Lipocalin (ng/g stool) Days UntreatedDSS only DSS + BMC321DSS + BMC322 1 4 6 7 Gut inflammation level During DSS treatment %mice * Preliminary results Days 7 14 21 0 AB DSS END C57bl/6J(SPF) BMC321 / BMC322; 3XW dosing

2 GI-related disorders BMC333 reduce tissue damage due to inflammation Study design for testing the anti-inflammatory effect of BMC333 in DSS-induced colitis murine model. Disease severity along study evaluated by Disease Activity Index (DAI) combined score following DSS administration in BMC333-treated and untreated groups. Mean histological score 2 0 1.5 0.5 1 2 0 1.5 0.5 1 8 0 6 2 4 Erosions Crypt_loss Sum_Score Histological evaluation from H&E staining of mice colon sections after DSS administration in BMC333-treated and untreated groups. WT mice (SPF) 8 14 15 1 End BMC3333XW DSS2% control (naïve) DSS only BMC333 Combined score control (naïve) DSS only 1 6 11 15 4 8 13 10 0 7.5 5 2.5 BMC333 BMC333x3/wk DSS2% p-value (day 15) <0.05 *** *** ** *

Antimicrobial resistance (AMR) 3 Targeting multi-drug resistant bacterium while preserving healthy gut microbiome C. difficile infection (CDI) www.prnewswire.com/news-releases/global-methicillin-resistant-staphylococcus-aureus-mrsa-drugs-market-to-reach-over-us-39-billion-by-2025-upsurge-in-the-consumption-of-antibiotics-across-the-globe-to-fuel-market-growth-observes-transparency-market-research-676949593.html MRSA infection $3.9Bn MRSA market in 2025 (est.) $5.4Bn Due mostly to hospitalization, the economic cost of CDI (est.) Most common hospital-acquired infections (Over 600,000 a year).Increasing cause of morbidity and mortality.Developing a selective anti-bacterial agent designed to inhibit the C. difficile toxin. * Desai et al. BMC Infectious Diseases (2016) 16:303; Toxins 2016, 8, 134 A collaboration between Biomica and the Nobel Prize Laureate Prof. Ada Yonath at the Weizmann Institute of Science.In-licensed IP and knowhow generated by Prof. Ada Yonath.Cause to tens of thousands of annual cases of mortality in the US. *

Upcoming advancements The potential for future drugs Predictions for patients’ response to ICI Responder Non-responder Responder Responder Responder Non-responder

Elran Haber, PhD, MBACEOPreviously served as the CEO of Therapix Biosciences (Nasdaq, TASE: TRPX), leading the company to a successful IPO on Nasdaq and advancing the Company's programs to clinical stage. Spent more than 10 years as Chairman and board member of several privately held, and publicly traded companies. Served in senior executive roles in various life science companies and a private investment firm. Holds a PhD in Pharmaceutical Science and an MBA in Finance & Financial Engineering, both from The Hebrew University of Jerusalem, Israel. An experienced management team Prof. Yehuda RingelCSOChief of the Gastroenterology and Hepatology Division of the Meir Medical Center in Israel; Professor of Medicine at Chapel Hill, North Carolina and is affiliated with University of North Carolina Hospitals. Has more than 30 years of diverse experiences, especially in Gastroenterology and translational research, and is an expert on IBS and functional motility disorders; Recipient of several prestigious awards. MD from Technion Institute of Technology, Israel. Shiri Meshner, PhDVP of Research & DevelopmentPreviously served as the head & principal investigator of the Dead Sea microbiology lab in the Dead Sea-Arava Science Center.Spent over 5 years working in the pharma industry both in the US and in Israel (OSI pharmaceuticals and Teva pharmaceuticals). Holds a PhD in systems microbiology from the Department of Physics of Complex Systems at The Weizmann Institute. Eyal PartukVP Finance10 years experience in corporate finance, public and private companies. Spent the last years as the CFO of a start-up company – involvement in over $200M private fundraising. Certificated CPA – Hebrew University of Jerusalem. Ernst & Young alumnus. Board of directors Ofer HavivChairmanMr. Ofer Haviv serves as Evogene’s (Nasdaq: EVGN) President and CEO since of late 2004. Doron Ben AmiDirectorMr. Doron Ben Ami is a highly experienced executive with a successful track record of more than 20 years of in the Pharma industry. Kinneret Savitsky, PhDDirectorDr. Kinneret Livnat-Savitzky is the CEO and board member of FutuRx Ltd (OrbiMed, J&J Innovation and Takeda’s accelerator), Kinneret has over 25 years of experience in senior leadership positions in the biopharmaceutical industry.

Prof. Yehuda RingelChief Division of Gastroenterology and Hepatology at Meir Medical Center, Israel. Professor of Medicine at Chapel Hill, North Carolina and is affiliated with University of North Carolina Hospitals. Prof. Willem M De VosProfessor and Chair of Microbiology at Wageningen University, the Netherlands and Professor of Human Microbiomics at the University of Helsinki, Finland. Prof. R. Balfour SartorServes as the Midget Distinguished Professor of Medicine, Microbiology and Immunology and Director of the Multidisciplinary IBD Center at the University of North Carolina, Chapel Hill. Prof. James VersalovicPathologist-In-Chief at Texas Children’s Hospital and Director of Texas Children’s Microbiome Center, Professor and Vice Chair of Pathology & Immunology at Baylor College of Medicine. Prof. David RubinSection chief of gastroenterology, hepatology, and nutrition at University of Chicago Medicine. Chair-elect of the National Scientific Advisory Committee of the Crohn’s and Colitis Foundation. Dr. Ravid StraussmanPrinciple investigator of the Tumor microenvironment, tumor microbiome and resistance to anti-cancer therapy lab at the Weizmann Institute of Science, Israel. World-class scientific advisory board & advisors

A phase 1, open-label study to evaluate the safety and tolerability of BMC128 in combination with anti-PD-1 in patients with non-small cell lung cancer (NSCLC), melanoma or renal cell carcinoma (RCC). are to explore efficacy variables in response to combined treatment with BMC128 and anti PD-1. Exploratory objectives POC first-in-human clinical trial to be initiated early 2022 expected to be enrolled in this phase I trial. 12-15 Patients of the BMC128 and anti PD-1 combination will be investigated as primary objective. Safety & tolerability is the expected start of this study, in a leading medical center in Israel. Q1 2022

Human microbiome-based therapeutics is a rapidly growing space, and represents a multi $Bn market opportunity. Biomica develops innovative microbiome-based therapeutics utilizing dedicated computational predictive biology tools. Biomica's computational tools and unique approach provide a significant differentiation. First-in-human POC study in cancer slated early 2022. Focus on high-value clinical programs for the development of therapies for antibiotic resistant bacteria, immuno-oncology and microbiome-related gastrointestinal (GI) disorders. Experienced management team, board of directors& world-class scientific advisory board. Summary

Thank you! info@biomica.com